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Assessment of Chest High-Field Magnetic Resonance Imaging in
Children and Young Adults With Noncystic Fibrosis Chronic
Lung Disease
Comparison to High-Resolution Computed Tomography and Correlation With
Pulmonary Function
Silvia Montella, MD,* Francesca Santamaria, MD,* Marco Salvatore, MD,† Claudio Pignata, MD,*
Marco Maglione, MD,* Paola Iacotucci, MD,* and Carmine Mollica, MD‡§
Objectives: Magnetic resonance imaging (MRI) has been proposed as a
radiation-free alternative to high resolution computed tomography (HRCT)
for the assessment and follow-up of chest disorders. Thus far, no study has
compared the efficacy of high-field MRI and HRCT in children and adults
with noncystic fibrosis (CF) chronic lung disease. The aims of our study
were: (1) to assess whether chest high-field MRI is as effective as chest
HRCT in identifying pulmonary abnormalities; and (2) to investigate the
relationships between the severity and extent of lung disease, and functional
data in patients with non-CF chronic lung disease.
Materials and Methods: Forty-one subjects (median age, 13.8 years; range,
5.9–29.3 years; 30 children/11 adults) with primary ciliary dyskinesia (n 
14), primary immunodeficiency (n  14), or recurrent pneumonia (n  13)
underwent pulmonary function tests, chest HRCT (120 kV, dose-modulated
mAs) and high-field 3.0-T MRI (HASTE; transversal orientation; repetition
time/echo time/flip angle/acquisition time, infinite/92 milliseconds/150°/
approximately 90 seconds). HRCT and MRI images were scored in consen-
sus by 2 raters using a modified version of the Helbich scoring system. The
maximal score was 25.
Results: HRCT and high-field MRI total scores were 11 (range: 1–20) and
11 (range: 1–17), respectively. There was good agreement between the 2
techniques for all scores (r  0.8). HRCT and MRI total scores, and extent
of bronchiectasis scores were significantly related to pulmonary function
tests (r  0.4, P  0.05). The MRI mucous plugging score was signifi-
cantly related to pulmonary function tests (r  0.4, P  0.05).
Conclusions: Chest high-field 3.0-T MRI appears to be as effective as
HRCT in assessing the extent and severity of lung abnormalities in non-CF
chronic lung diseases, and might be a reliable radiation-free option to HRCT.
Key Words: high-field MRI, HRCT, chronic lung disease, pulmonary
function
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The last 2 decades have seen an increase in the prevalence ofchronic lung disorders in children and adults. This is probably
because of 2 factors. First, patients with cystic fibrosis (CF), which
is the most frequent congenital chronic lung disease in white
subjects, survive longer than in the past.1 Second, thanks to new
diagnostic tools, other pulmonary disorders, including non-CF bron-
chiectasis, primary ciliary dyskinesia (PCD), and interstitial lung
disease, are now more easily identified.
Chest computed tomography (CT), particularly high-resolu-
tion CT (HRCT), has become the imaging technique of choice for
the evaluation of lung abnormalities at any age.2,3 However, CT has
been criticized for its ionizing radiation burden and the possible
consequences of cumulative doses, particularly in relation to fre-
quent follow-up examinations in patients with chronic disorders, in
pregnancy, and in children.4 Therefore, the radiation dose during CT
should be ideally tailored to the type of study being performed and
to the size of the patient, a practice that is increasing but is by no
means universal.4 This issue is especially relevant in the pediatric
setting because children are more sensitive to radiation than are adults.5
Chest magnetic resonance imaging (MRI) has been proposed
as a radiation-free technique for the assessment and follow-up of
several chest disorders.6–12 However, its application in lung disease
has long been limited by technical problems, namely a low signal-
to-noise ratio because of the low proton density of the lung, and
artifacts because of cardiac and breathing motion or to air/soft tissue
transition.13 Several studies have compared the efficacy of chest
morphologic MRI, mainly 1.5-T MRI, and other traditional imaging
techniques in children and adults with lung disorders.9,11,14–21 The
overall conclusion of these studies is that MRI is comparable to
conventional chest x-ray and CT, thus indicating that chest MRI may
be a reliable radiation-free option in lung disorders.9,11,14–22
High-field 3.0-T MRI has several advantages over 1.5-T MRI,
namely, better temporal and/or spatial resolution and faster acqui-
sition times.15 To our knowledge, no study has compared chest
HRCT to high-field MRI in children and adults with non-CF chronic
lung disease. The primary aim of this study was to assess whether
high-field 3.0-T MRI is as effective as HRCT in identifying pulmo-
nary abnormalities in children and young adults with non-CF chronic
lung disease. The secondary aim was to investigate the relationships
between the severity and extent of lung structural changes, identified
with HRCT and MRI, and pulmonary function tests (PFTs).
MATERIALS AND METHODS
Patients
Our institutional review board approved the study, and in-
formed written consent was obtained from the parent/legal guardian
of each child and from adult patients. Sixty-three patients with
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non-CF chronic lung disease were seen at our Department between
March 2007 and June 2008. Twenty-two of them were excluded
because of acute respiratory infection and/or mental retardation or
other conditions that could compromise compliance to HRCT and
MRI, namely, those with age less than 5 years and claustrophobic.
Therefore, we prospectively enrolled in the study 41 subjects (25
males; median age, 13.8 years; range, 5.9–29.3 years; 30 children/11
adults) with chronic lung disorders because of PCD (group A; n 
14; 10 males; median age, 15.2 years; range, 10.4–29.3 years), to
primary immunodeficiency (group B; n  14; 9 males; median age,
13.4 years; range, 6.2–20.5 years), or to recurrent pneumonia (group
C; n  13; 6 males; median age, 11.1 years; range, 5.9–24.6 years).
In all patients, CF had been previously excluded on the basis of
normal sweat chloride test and negative results at CF gene mutation
analysis for the most common mutations in our population, which
accounted for 94% of mutant alleles found locally. In group A, PCD
was suspected on the basis of clinical features and/or situs viscerum
inversus.23 Diagnosis was confirmed by light microscopy and by
electron microscopy analysis of cilia ultrastructure on nasal brush-
ing. Group B consisted of patients with primary immunodeficiency
including chronic granulomatous disease (n  6), hyper-IgM syn-
drome (n  1), IgA deficiency (n  2), common variable immuno-
deficiency (n  3), and autosomal recessive (n  1), or X-linked
(n  1) agammaglobulinemia. Patients from group C were diag-
nosed as having recurrent pneumonia, defined as 2 episodes in a
single year or3 episodes ever.24 Nasal ciliary electron microscopy
findings and detailed immunologic investigations were unremark-
able in all group C subjects.
Patients underwent chest HRCT for clinical reasons, ie, per-
sistence of chronic cough and/or focal abnormality at chest x-ray
unresponsive to medical treatment, and/or discrepancy between lung
function or clinical status and chest x-ray. In all patients chest MRI
and HRCT were performed on the same day.
HRCT Scanning
The HRCT scan was performed with a 4-slice CT scanner
(Aquilion, Toshiba, Japan) and a bodyweight adapted protocol
(adolescents: 120 kV, 140 mAs; children over 45 kg: 120 kV, 65
mAs; children over 35 kg: 120 kV, 45 mAs; children below 35 kg:
120 kV, 30 mAs), with 1x4 mm collimation, 10 mm gap, 0.5
seconds rotation time, automatic exposure control, multiple inspira-
tory breath holds of 3 seconds each, with the patient in a supine
position. Scanning extended from the lung apices to below the
costophrenic angles. The field of view of each sequence was patient-
adapted. Images were reconstructed using a high-resolution algo-
rithm. The total time for acquisition of the images was approxi-
mately 5 minutes, including positioning of the patient. Contrast
medium was not administered. For documentation of radiation
exposure, the dose length product was recorded, and the effective
dose (E) and the weighted CT dose index were calculated. A lung
window setting (1500/500 Hounsfield unit) was used for image
analysis. Images were reviewed on a workstation (iMac Ma-
cOS10.4/OsiriX v.2.7.5 32 bit).
MR Scanning
MRI was performed with a 3.0-T MR scanner (Magnetom
Trio, Siemens Erlangen, Germany), a maximum gradient strength of
40 mT/m, a slew rate of 200 mT/m/ms, and 32 radiofrequency
channels. We used a dedicated 12-element integrated matrix coil
system that covered the whole thorax for signal reception. It con-
sisted of 1 anterior and 1 posterior flexible phased-array coil, each
containing a set of 6 receiver elements. The applied sequence was a
T2-weighted half-Fourier single-shot turbo spin-echo (HASTE) se-
quence, performed using an electrocardiograph-gating to reduce
cardiac motion artifacts, and respiratory-gating by a navigator signal
that monitored the diaphragm position. The field of view was
patient-adapted. Sequence parameters were: repetition time/echo
time/flip angle, infinite/92 milliseconds/150 degrees; 25 to 30 slices;
slice thickness, 5 mm; distance factor, 20%; transversal orientation
(matrix, 380  256); acquisition time, approximately 90 seconds.
Parallel imaging was used for all measurements using the GRAPPA
(Generalized Autocalibrating Partially Parallel Acquisition) algo-
rithm with an acceleration factor of 2 and 24 reference lines. No
patient required sedation. Door-to-door time was 5.5 minutes (range,
5–8). All HRCT and MRI studies were of diagnostic quality and
were well tolerated.
Image Evaluation
All identifying information was removed from the scans. To
compare chest MRI and HRCT results, we scored HRCT and MR
scans, using a modified version of the scoring system developed by
Helbich et al for CF.25 The original Helbich score includes severity
and extent of bronchiectasis, severity of peribronchial wall thicken-
ing, extent of mucous plugging, generation of bronchial divisions
involved by bronchiectasis or plugging, extent of sacculations or
abscesses, severity of bullae, severity of emphysema, severity of
collapse or consolidation, and severity of mosaic perfusion.25 We
excluded the severity of mosaic perfusion from imaging evaluation
because it cannot be assessed by morphologic MRI.18 Therefore, the
maximum total score was 25 points, and not 27 (Table 1). We
evaluated HRCT and MRI using the modified Helbich CT score as
follows: (1) for the categories “severity of bronchiectasis” and
“severity of peribronchial wall thickening”, we recorded the most
prevalent degree of severity; (2) it was not possible to assess
peribronchial wall thickening in the presence of mucous plugging;
(3) hyperintensity on images had to be present for an MRI diagnosis
of mucous plugging; (4) if mucous plugging was seen within the
periphery of a lung segment, bronchiectasis was scored also in that
segment; (5) sacculations/abscesses were defined as circular struc-
tures with a minimum diameter of 1.5 cm that were air-filled or
showed an air-fluid level; (6) a size of 2 cm was required for a
diagnosis of collapse/consolidation; (7) emphysema was defined as
an area of decreased signal (compared with the surrounding lung
parenchyma) because of a reduction of vessel and parenchymal
density; and (8) in case of lobectomy or segmentectomy, the max-
imum scores for “severity of bronchiectasis” and “severity of col-
lapse/consolidation” were arbitrarily assigned to the missing lobe/
segments. The assessment of “extent of bronchiectasis” took into
account the number of missing segments.
Six lobes were examined; the lingula was scored separately.
In patients with situs viscerum inversus, the right lung was the lung
in which the middle lobar bronchus and the corresponding middle
lobe were identified at scans. The images were evaluated in consen-
sus and in a blinded fashion by 2 experienced observers (1 radiol-
ogist with 8 years and 1 pediatric pulmonologist with 15 years of
experience in CT interpretation). Raters were unaware of any clin-
ical data that could have biased their interpretation of the images.
MR and HRCT scans were presented to the raters in a random,
independent order. HRCT scans were scored 8 weeks after the MR
images, so that the HRCT findings would not influence the raters’
judgments of the MRI findings.
Lung Function Assessment
Forced vital capacity (FVC), forced expiratory volume at 1
second (FEV1), the FEV1/FVC ratio, and forced expiratory flow at
25% to 75% of the pulmonary volume (FEF25–75) were measured,
on the same day as chest imaging, with spirometry according to
American Thoracic Society.26 A FEV1 85% predicted was con-
sidered normal. Patients underwent CT and MR studies in the
morning and pulmonary function tests in the afternoon.
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Statistical Analysis
Results are expressed as median and range values. One-way
analysis of variance (ANOVA) and 2 test were used to compare
clinical, functional, and radiologic data from the 3 groups of pa-
tients. We used Spearman rank correlation coefficient (rho) to assess
correlations among the variables and agreement between HRCT and
MRI scores. A coefficient of 0.8 represents good agreement. A
2-sided P  0.05 was significant. Data were analyzed with SPSS-
PC, release 13.0, SPSS Inc (Chicago, IL).
RESULTS
HRCT and MRI identified lung abnormalities in all patients.
Bronchiectasis, peribronchial wall thickening, mucous plugging,
and collapse/consolidation were the most frequent abnormalities
both in the overall study population and in each group (Table 2).
MRI failed to detect bullae in 1 patient, but identified peribronchial
wall thickening and mucous plugging more frequently than HRCT.
There were no other differences in the prevalences of lung abnor-
malities identified by the 2 techniques.
There was a good or excellent agreement between HRCT and
MRI for all scores (Table 3). Figure 1 shows the excellent correla-
tion between the total scores of HRCT and MRI (r 0.97). We were
unable to compute agreement between HRCT and MRI scores for
generation of bronchial divisions involved by bronchiectasis or
plugging in group A, or for extent of sacculations/abscesses and
severity of bullae in group C because of the constant value attributed
to these categories at HRCT and at MRI in all subjects (Table 4).
Agreement between HRCT and MRI was good or excellent in each
group for the remaining abnormalities. Group B patients had lower
HRCT and MRI scores than patients of groups A and C for severity
of bronchiectasis (P  0.03 and P  0.047, respectively), severity
of peribronchial wall thickening (P  0.006 and P  0.004,
respectively), generation of bronchial divisions involved by bron-
chiectasis or plugging (P  0.001 and P  0.001, respectively), and
total scores (P  0.005 and P  0.002, respectively). Group A
subjects had the highest HRCT and MRI scores for extent of
bronchiectasis (P  0.009 and P  0.01, respectively), extent of
mucous plugging (P  0.005 and P  0.007, respectively), and
severity of collapse/consolidation (P  0.02 and P  0.02, respec-
tively). No other significant intergroup differences were found.
Spirometry was performed by 34 co-operating patients (83%).
FVC, FEV1, and FEF25–75 were 97% predicted (range, 52%–140%),
TABLE 2. Prevalences of Lung Abnormalities Identified With HRCT and MRI in the Whole Study
Population and in Each Group
LUNG ABNORMALITY
Whole Study
Population Group A Group B Group C
HRCT MRI HRCT MRI HRCT MRI HRCT MRI
Bronchiectasis 76% 76% 93% 93% 50% 50% 85% 85%
Peribronchial wall thickening 71% 73% 100% 100% 43% 43% 69% 77%
Mucous plugging 73% 78% 93% 100% 43% 43% 85% 92%
Sacculations or abscesses 12% 12% 7% 7% 29% 29% 0% 0%
Bullae 10% 7% 14% 14% 14% 7% 0% 0%
Emphysema 10% 10% 14% 14% 7% 7% 8% 8%
Collapse or consolidation 66% 66% 93% 93% 43% 43% 62% 62%
TABLE 1. Modified Helbich Scoring System for HRCT and MRI
Category
Score
0 1 2 3
Severity of bronchiectasis Absent Mild (lumen slightly greater
than the diameter of
adjacent blood vessel)
Moderate (lumen 2 to 3 times
the diameter of the vessel)
Severe (lumen 3 times the
diameter of the vessel)
Severity of peribronchial wall
thickening
Absent Mild (wall thickness equal to
the diameter of adjacent
vessel)
Moderate (wall thickness
greater than and up to twice
the diameter of adjacent
vessel)
Severe (wall thickness more
than twice the diameter of
adjacent vessel)
Extent of bronchiectasis Absent 1–5* 6–9* 9*
Extent of mucous plugging Absent 1–5* 6–9* 9*
Extent of sacculations or
abscesses




Absent Up to the 4th generation Up to the 5th generation Up to the 6th generation and
distal
Severity of bullae Absent Unilateral (not 4) Bilateral (not 4) 4
Severity of emphysema Absent 1–5* 5* Not applicable
Severity of collapse or
consolidation
Absent Subsegmental Segmental or lobar Not applicable
*Numbers of bronchopulmonary segments.
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91% predicted (range, 28%–132%), and 71% predicted (range,
7%–129%), respectively. The FEV1/FVC ratio was 79% (range,
45%–101%). Twenty patients (59%) had a normal FEV1. HRCT and
MRI total scores were significantly related to FVC (r  0.4, P 
0.03; and r  0.4, P  0.02, respectively), FEV1 (r  0.4, P 
0.015; and r  0.4, P  0.008, respectively), the FEV1/FVC ratio
(r  0.4, P  0.03; and r  0.4, P  0.02, respectively), and
FEF25–75 (r  0.4, P  0.02; and r  0.4, P  0.01, respec-
tively). There was a significant correlation between HRCT and MRI
scores for extent of bronchiectasis and FEV1 (r  0.4, P  0.03;
and r  0.4, P  0.03, respectively), the FEV1/FVC ratio (r 
0.4, P  0.02; and r  0.4, P  0.02, respectively), and
FEF25–75 (r  0.4, P  0.04; and r  0.4, P  0.03, respec-
tively). Unlike HRCT, the MRI mucous plugging score was signif-
icantly related to FVC (r  0.4, P  0.03), FEV1 (r  0.4, P 
0.02), the FEV1/FVC ratio (r  0.4, P  0.04), and FEF25–75
(r  0.4, P  0.04).
The median dose length product of the HRCT studies was
84.2 mGy  cm (range, 43.7–210.8). The median E was 0.76 mSv
(range, 0.39–1.88). The median weighted CT dose index was 3.12
mGy (range, 2.3–5.85).
Figures 2 to 5 are examples of images obtained with HRCT
and MRI. Figure 2A shows an area of consolidation in the middle
lobe obtained with HRCT in a boy affected by PCD and situs
viscerum inversus. The area was well visualized also with MRI (Fig.
2B). Figure 3 shows images of a large abscess in the right lower lobe
obtained with HRCT (panel A) and with MRI (panel B) in a male
with chronic granulomatous disease. Figure 4 shows HRCT (panel
A) and MRI (panel B) images of bronchiectasis, bronchial wall
thickening and mucous plugging in the left lower lobe in a male with
a history of recurrent pneumonia. Figure 5A shows an HRCT image
of severe bronchiectasis with partial parenchymal destruction in the
middle lobe in a female with PCD. The same abnormalities were
well visualized also with MRI (Fig. 5B).
DISCUSSION
In this study, we compared the efficacy of chest HRCT and
high-field MRI in the assessment of the severity and extent of lung
abnormalities in children and young adults with non-CF chronic
lung disease. The agreement between the 2 techniques was good or
excellent for all the abnormalities considered. Bronchiectasis, peri-
bronchial wall thickening, mucous plugging, and collapse/consoli-
TABLE 3. Median HRCT and MRI Scores, and Their
Agreement, in the Whole Study Population
Category HRCT Score MRI Score r
Severity of bronchiectasis 2 (0–3) 2 (0–3) 0.96
Severity of peribronchial wall
thickening
2 (0–2) 2 (0–2) 0.94
Extent of bronchiectasis 1 (0–3) 1 (0–3) 0.97
Extent of mucous plugging 1 (0–3) 1 (0–3) 0.93
Extent of sacculations or abscesses 0 (0–3) 0 (0–3) 0.89
Generation of bronchial divisions
involved (bronchiectasis or
plugging)
3 (0–3) 3 (0–3) 0.95
Severity of bullae 0 (0–3) 0 (0–3) 0.86
Severity of emphysema 0 (0–2) 0 (0–2) 0.89
Severity of collapse or
consolidation
1 (0–2) 1 (0–2) 1
Total score 11 (1–20) 11 (1–17) 0.97
Values are expressed as median and ranges (in parentheses).
TABLE 4. Median HRCT and MRI Scores, and Their Agreement, in Each Group
Category
Group A Group B Group C
HRCT Score MRI Score r HRCT Score MRI Score r HRCT Score MRI Score r
Severity of bronchiectasis 2 (0–3) 2 (0–3) 0.86 0.5 (0–2) 0.5 (0–2) 1 2 (0–3) 2 (0–3) 1
Severity of peribronchial wall thickening 2 (1–2) 2 (1–2) 1 0 (0–2) 0 (0–2) 1 2 (0–2) 2 (0–2) 0.82
Extent of bronchiectasis 2 (0–3) 2 (0–3) 0.97 0.5 (0–3) 0 (0–3) 0.91 1 (0–3) 1 (0–3) 1
Extent of mucous plugging 2 (0–3) 2 (1–3) 0.95 0 (0–3) 0 (0–3) 1 1 (0–3) 1 (0–3) 0.84
Extent of sacculations or abscesses 0 (0–1) 0 (0–1) 1 0 (0–3) 0 (0–3) 0.85 0* 0* NA
Generation of bronchial divisions involved
(bronchiectasis or plugging)
3* 3* NA 2 (0–3) 1 (0–3) 0.93 3 (0–3) 3 (0–3) 1
Severity of bullae 0 (0–3) 0 (0–3) 1 0 (0–3) 0 (0–3) 0.73 0* 0* NA
Severity of emphysema 0 (0–1) 0 (0–1) 0.8 0 (0–2) 0 (0–1) 1 0 (0–2) 0 (0–2) 1
Severity of collapse or consolidation 2 (0–2) 2 (0–2) 1 0 (0–2) 0 (0–2) 1 1 (0–2) 1 (0–2) 1
Total score 12 (6–20) 12 (5–17) 0.94 4 (1–17) 3.5 (1–16) 0.92 10 (1–15) 10 (1–16) 0.97
Values in parentheses are ranges.
*Range values are not reported because all patients had the same score.
NA indicates not applicable (see text).
FIGURE 1. Agreement between HRCT and MRI total scores
in the whole population. Twenty-three points are shown be-
cause 7 values overlap.
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dation were the most frequent abnormalities. HRCT and MRI total
scores, and extent of bronchiectasis scores were significantly related
to PFTs. Finally, unlike HRCT, the MRI mucous plugging score was
significantly related to PFTs.
The management of non-CF chronic lung disease is based on
clinical assessment and sputum cultures combined with pulmonary
function and lung imaging evaluation.27,28 However, PFTs are
relatively insensitive markers of early disease and fail to detect
changes in the peripheral airways. Chest CT provides a more
accurate picture of the type, distribution and extent of lung changes
than either PFTs or chest radiography,29 but entails exposure to
ionizing radiation.4 Therefore, there is a need for a sensitive tech-
nique that assesses lung changes without exposing patients to
ionizing radiation.
Experience with lung MRI, particularly high-field MRI, is
limited.22 To determine the clinical value of chest high-field 3.0-T
MRI scanning and its potential as a surrogate outcome measure in
children and young adults with non-CF chronic lung disease, we
compared 3.0-T MRI to HRCT, using a scoring system, ie, the
modified Helbich score.18 Although this score was devised for CF
patients,25 we used it because there is no scoring system specific for
non-CF chronic lung diseases and because we found it to be easily
adaptable to MRI. Our data show that chest MRI findings coincide
with HRCT findings, thereby supporting the concept that MRI might
be an alternative, radiation-free method for pulmonary assessment in
non-CF chronic lung disease as well as in CF.17–19
Chest MRI has several advantages over CT. First, being
radiation-free it can be repeated (eg, in case of artifacts), and is thus
FIGURE 3. Images of a 19-year-old man with chronic granu-
lomatous disease. A, Transversal HRCT showing a large ab-
scess in the right lower lobe. B, Corresponding transversal
MR image.
FIGURE 2. Transversal HRCT (A) and transversal MR (B) im-
ages of a 10.4-year-old boy with primary ciliary dyskinesia
and situs viscerum inversus. Both scans clearly depict an area
of consolidation in the middle lobe.
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suitable for long-term disease monitoring. Second, MRI identifies
various characteristics of lung tissue, allows a precise characteriza-
tion of the lesion and assesses function, eg, lung perfusion and/or
ventilation, and respiratory mechanics.13,30 In selected patients,
chest MRI may be more informative than CT. In fact, Lutterbey et
al demonstrated that 3.0-T MRI of the lung performed slightly better
than CT in the evaluation of disease activity in patients with
interstitial lung disorders.8 Thus, structural information and func-
tional data are obtained in a single examination, thereby reducing
imaging costs and increasing the patient’s compliance.19 Finally,
unlike CT, chest MRI easily distinguishes between mucous plugging
and bronchial wall thickening even in the peripheral airways.17 This
finding, probably because of the elevated proton density of mucous,
is relevant because peripheral mucous plugging is a sensitive marker
of early small airway disease, particularly in PCD.31 Interestingly,
we found that, unlike HRCT, the MRI mucous plugging score was
significantly related to PFTs.
On the other hand, the spatial resolution of MRI is lower than
that of CT, and slight morphologic changes such as peripheral
bronchiectasis without bronchial wall thickening or nodules smaller
than 5 mm are not consistently visualized by MRI.17,32 Another
disadvantage of MRI is that the specific absorption rate increases
with field strength. However, the specific absorption rate can be
decreased by using transmit/receive array coils, by reducing the
number of slices, and by using parallel imaging techniques.33 Other
potential drawbacks of MRI are limited access to the technology,
long acquisition times and high costs. However, we believe that the
benefits of MRI outweigh the greater discomfort for the patient and
the higher costs. Technical progress will hopefully lead to lower
costs, shorter examination times and higher image resolution.
To our knowledge, this is the first time that 3.0-T MRI has
been used for the quantitative analysis of pulmonary abnormalities
in children and adults with non-CF chronic lung disorders. Although
a field strength of 1.5 T is generally used in clinical practice, MR
whole-body units operating at field strengths of 3.0 T and beyond are
increasingly being installed in research institutions and in clinical
facilities.15,21,34 Previous studies showed that 1.5-T MRI and 3.0-T
MRI have comparable image quality.35,36 However, the overall scan
time is shorter with 3.0-T MRI, at a constant image resolution,
thanks to parallel imaging.36 Moreover, a higher lesion contrast can
be expected at 3.0 T.35 On the other hand, the effects of magnetic
susceptibility on T2 and on T2* increase with the field strength, and
this may degrade image quality.35 Lastly, artifacts from cardiac and
respiratory motion tend to be more pronounced with 3.0-T imaging,
particularly in the lower and anterior sections of the chest.37
The scanner we used has several advantages over 1.5-T: (1) it
has a high-speed and a high-strength gradient system; (2) it is
equipped with multiple phased-array coils and receiver channels;
and (3) it has acquisition acceleration techniques, such as parallel
imaging. Parallel acquisition techniques improve image quality by
shortening the echo times of single-shot sequences.38 Despite the
high-field used, shorter echo times result in fewer blurring artifacts
and less signal decay caused by T2* effects. Another advantage of
the system we used is that cardiac- and respiratory-gating reduce
artifacts because of heart/great vessels/chest wall motion thereby over-
coming the need for sedation even in poorly cooperating subjects.
Our study has several limitations. HRCT images were ac-
quired with the inspiratory breath-hold technique, whereas MR
images were acquired with the respiratory-gating technique. However,
our study population consisted mainly of children who were unable to
hold their breath for a long time, despite training. In our HRCT
protocol, sections were acquired during multiple inspiratory breath
holds of 3 seconds each. Unfortunately, the MR HASTE sequence
requires a breath hold of approximately 18 seconds.17,18 Therefore, we
FIGURE 5. Images of a 20.9-year-old woman with primary ciliary
dyskinesia. A, Transversal HRCT showing severe bronchiectasis
with partial destruction in the middle lobe. B, Corresponding
transversal MR image. The severe bronchiectasis and partial paren-
chymal destruction in the middle lobe are clearly visualized.
FIGURE 4. Transversal HRCT (A) and transversal MR (B) im-
ages of a 20-year-old man with history of recurrent pneumo-
nia. HRCT and MRI show bronchiectasis, bronchial wall
thickening, and mucous plugging in the left lower lobe.
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used respiratory gating to overcome the lack of cooperation in children,
and applied it also to adults for the sake of uniformity.
Other limitations of our study are that HRCT scans were
performed for clinical purposes, MR sequences other than HASTE
were not carried out, and functional and longitudinal MRI data were
not obtained. Moreover, the echo time used was not optimal.
However, this did not seem to affect our findings as shown by the
comparable HRCT and MRI scores. In addition, most of our patients
had advanced chronic lung disease, and we did not include infants in
our evaluation. Therefore, whether high-field MRI is as sensitive as
HRCT, also in patients with early morphologic changes, cannot be
deduced from the present study.
Finally, another drawback of our study is that images were
evaluated in consensus using a modified Helbich score. This ap-
proach, also used in a previous study of CF patients,18 was chosen
by us because of scarce experience in reading morphologic MR
images of chronic lung diseases in CF and non-CF patients, and
because no validated MRI score is available. Therefore, our 2
evaluators had to familiarize themselves with reading the MR
images and with applying the adapted scoring system we used.
Clearly, a scoring system should be devised for evaluations of
morphologic MR images in patients with chronic lung diseases.
In conclusion, chest high-field 3.0-T MRI appears to be as
effective as HRCT in the assessment of the extent and severity of
lung disease. Therefore, it might be considered a reliable radiation-
free option to HRCT and be proposed for follow-up examinations.
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